This page is intended for members of the public.
Medical Information can be contacted at medinfo@daiichi-sankyo.co.uk or on 0800 028 5122.
To report an adverse event experienced whilst taking a Daiichi Sankyo product, please report the event to:
Tel: 0800 028 5122
Email: pharmacovigilance@daiichi-sankyo.co.uk
Information on the reporting of adverse events can be obtained from https://yellowcard.mhra.gov.uk/
Medicine displayed with black triangle symbol ▼: This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects.
Products
| Product | Summary of Product Characteristics (SmPC) | Patient Information Leaflet (PIL) |
|---|---|---|
| Efient (prasugrel hydrochloride) | ||
| Enhertu▼ (trastuzumab deruxtecan) | ||
| Lixiana (edoxaban tosilate) | ||
| Motifene (diclofenic sodium) | UK SmPC | UK PIL |
| Nilemdo▼ (bempedoic acid) | ||
| Nustendi▼ (bempedoic acid, ezetimibe) | ||
| Olmetec (olmesartan medoximil) | UK SmPC | UK PIL |
| Olmetec Plus 20 mg/12.5 mg & 20 mg/12.5 mg (olmesartan medoximil, hydrochlorothiazide) | UK SmPC | UK PIL |
| Olmetec Plus 40 mg/12.5 mg olmesartan medoximil, hydrochlorothiazide) | UK SmPC | UK PIL |
| Sevikar (olmesartan medoximil, amplodipine besilate) | UK SmPC | UK PIL |
| Sevikar HCT (olmesartan medoximil, amplodipine besilate, hydrochlorothiazide) | UK SmPC | UK PIL |
DSC/22/0038 March 2022
